These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6431436)

  • 21. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Preliminary experience with achieving immune tolerance in patients with hemophilia A and circulating factor VIII inhibitor].
    Scharf R; Kucharski W; Lopaciuk S; Celińska W; Dmytrow A; Domański K; Gonet S; Miastkowski Z; Nowakowska I; Przybylski A
    Acta Haematol Pol; 1991; 22(1):92-9. PubMed ID: 1823972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunosuppressive treatment of a spontaneous inhibitor hemophilia A using cyclophosphamide, vincristine and prednisone following prior Factor VIII stimulation].
    Dürig J; de Wit M; Fiedler W; Marx G; Hossfeld DK
    Schweiz Med Wochenschr; 1996 Nov; 126(47):2026-31. PubMed ID: 8984611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J
    Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII.
    Sultan Y; White GC; Aronstam A; Bosser C; Brackmann HH; Brochier G; Gormsen J; Mariani G; Roberts HR; Scarabin Y
    Nouv Rev Fr Hematol (1978); 1986; 28(2):85-9. PubMed ID: 3090516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors.
    McMillan CW; Shapiro SS; Whitehurst D; Hoyer LW; Rao AV; Lazerson J
    Blood; 1988 Feb; 71(2):344-8. PubMed ID: 3122859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of inhibitor patients with activated prothrombin complex concentrates.
    Penner JA
    Prog Clin Biol Res; 1984; 150():291-308. PubMed ID: 6431434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.
    Peerschke EI; Castellone DD; Ledford-Kraemer M; Van Cott EM; Meijer P;
    Am J Clin Pathol; 2009 Apr; 131(4):552-8. PubMed ID: 19289591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of factor VIII:C inhibitors and treatment response in severe hemophilia A patients.
    Luna-Záizar H; Esparza-Flores MA; López-Guido B; Aguilar-López LB; Cortés Alvarez CR; Jaloma-Cruz AR
    Int J Lab Hematol; 2009 Dec; 31(6):673-82. PubMed ID: 18771497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term remission after i.v. immunoglobulin therapy in acquired antihemophilic factor hemophilia with systemic lupus erythematosus].
    Pirner K; Rösler W; Kalden JR; Manger B
    Z Rheumatol; 1990; 49(6):378-81. PubMed ID: 2128157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Characterization of the factor VIII inhibitor in a patient with chronic renal failure].
    Uemura Y; Niiya K; Takeuchi T; Miyoshi I
    Rinsho Ketsueki; 1991 Jan; 32(1):39-42. PubMed ID: 1708430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.
    Sahud MA; Pratt KP; Zhukov O; Qu K; Thompson AR
    Haemophilia; 2007 May; 13(3):317-22. PubMed ID: 17498082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune tolerance by intermittent factor VIII boluses in two high responder hemophilia A patients.
    Landolfi R; de Cristofaro R; Lazzareschi I; Riccardi R; Mariani G
    Haematologica; 2000 Oct; 85(10 Suppl):73-4. PubMed ID: 11187877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Remission of a non-haemophilic patient with acquired factor VIII inhibitor treated with infusion of factor VIII and corticosteroid].
    Honda J; Egami K; Osabe S; Natori H; Nakamura E; Tanaka K; Naitou K; Kaji M
    Rinsho Ketsueki; 1989 Apr; 30(4):520-4. PubMed ID: 2504978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transient factor VIII inhibitor in a hemophilia patient after staphylococcal septic shock syndrome.
    Yamamoto K; Niiya K; Shigematu T; Kiguchi T; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Shima M; Harada M
    Int J Hematol; 2000 Dec; 72(4):517-9. PubMed ID: 11197224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.